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Poster Session-I 69respectively; median number of prior regimens in both groups was 5.
Twelve patients (30%) in group A and 42 patients (69%) in group B
had a prior autologous SCT.
Results: Median follow up in surviving patients was 8.2 years in
group A and 2 years in group B. Reduced-intensity conditioning
(RIC) regimens were used in 15 patients (37%) in group A, and 56
patients (92%) in group B. Cumulative TRM in group A and B
was 57% and 31%, respectively (p 5 0.006). Disease progression
was seen in 15 patients (37.5%) in group A and in 31 patients
(50%) in group B (p 5 0.22). Time to progression from allo SCT
was 10.1 moths, with no significant difference between the 2 groups
(p5 0.85). As shown in Figures 1 and 2, patients in group B had sig-
nificantly longer PFS (7.3 vs. 4.8 months; p5 0.03, log rank test) and
OS (13.1 Months vs. 5.9 months; p5 0.008, log rank test). Grade II-
IV acute GVHD was seen in 21 patients (52%) in group A, and 21
patients (34%) in group B (p 5 0.09). Limited or extensive chronic
GVHD was seen in 15 patients (37%) in group A, and 20 patients
(32%) in group B (p 5 0.67). At the time of this analysis, 3 patients
in group A and 18 in group B were alive, while 2 patients in group A
and 12 in group B were alive and in remission.
Conclusions: Patients transplanted after January 2000 although
older and having failed a prior ASCT had significantly lower
TRM, lower incidence of acute GVHD and significantly longer
PFS and OS.185
HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANS-
PLANTATION FOR MULTIPLE MYELOMA: ACHIEVEMENT OF COMPLETE
REMISSION IS ASSOCIATED WITH IMPROVED SURVIVAL
Kumar, L., Ghosh, J., Ganessan, P., Gupta, A., Hariprasad, R. All India
Institute of Medical Sciences, New Delhi, India
We analyzed results of 108 patients of multiple myeloma who un-
derwent autologous stem cell transplantation (ASCT). Patients’ me-
dian age was 52 years (range, 26 to 68 years), M:F : 78 : 30. High
dosemelphalan (200mg/m2) was used for conditioning. 66 (61%) pa-
tients had evidence of chemo-sensitive disease prior to transplant. Fol-
lowing ASCT 79.6% of patients responded; complete (CR) - 36%,
very good partial response (VGPR) -29.6%, and partial response
(PR) -13.9%.CRratewas higher for patientswith chemo-sensitive dis-
ease; 33/66patients (50.0%) achievedCRcomparedwith7/42 patients
(14.3%) with progressive disease, p\.01. At a median follow up of 70
months , the median overall (OS) and event-free survival (EFS) is 71
and 42months, respectively . Estimated overall and event-free survival
at 60 months is 54.4%6 0.05 %(SE) and 49.3%6 0.05(SE), respec-
tively.Forpatientswithpre-transplantchemo-sensitivediseasemedian
OS (102 vs 38 months ,p\.0003) and EFS (96 vs for 21 month-
s,p\.0002) is significantly higher. Mean OS for patients with CR is
148.99 months (95% CI 116.75–181.23) (median not reached) and
for those with VGPR is 73.81 (95% CI 58.91–88.71) (median not
reached) ,p\0.04. Median OS for patients with PR, stable disease
and thosewithprogressive disease is 39, 24 and11months, respectively
(p\0.0003). Median EFS for patients with CR is 129.9 months (95%
CI 101.3–158.5) and 52.4 months (95% CI 41–63.8) for those with
VGPR ,p\.03. Median EFS for patients with PR, stable and
progressive disease is 20, 15 and 5 months respectively, p\0.0001.
Conclusion : Survival is significantly better for patients with pre-
transplant chemo-sensitive disease and those who achieve complete
remission following transplant.186
BUSULFANANDCYCLOPHOSPHAMIDEHAS SIMILAROUTCOMES TOHIGH
DOSE MELPHALAN AS A PREPARATIVE REGIMEN FOR AUTOLOGOUS
STEMCELL TRANSPLANTATION IN PATIENTSWITHMULTIPLEMYELOMA
Mahindra, A.1, Bolwell, B.1, Rybicki, L.2, Dean, R.1, Pohlman, B.1,
Sobecks, R.1, Andresen, S.1, Sweetenham, J.1, Kalaycio, M.1, Copelan, E.1
1Cleveland Clinic, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
High dose chemotherapy (HDC) with autologous stem cell trans-
plant (ASCT) has been shown to increase the rate of complete re-
sponse and prolong survival in multiple myeloma (MM). We
report a single-institution experience comparing two conditioning
regimens, busulfan (oral dose, 16mg/kg; intravenous dose 12.8mg/kg) and cyclophosphamide (120mg/kg) (BuCy) versus high dosemel-
phalan (200 mg/m2) (HDM). Between January 2000 and March
2008, 152 patients (pts) with MM underwent HDC with ASCT us-
ing either BuCy (n5 117; 73 pts (62%) received oral Bu) or HDM (n
5 35) in sequential cohorts as the preparative regimen. 61 patients
(52%) in the BuCy group and 26 patients (74%) in the HDM group
were male (p 5 0.02). The two groups were otherwise similar with
respect to age, ISS stage, b2 microglobulin, number of prior chemo-
therapy regimens, prior radiation therapy, FEV1 and DLCOc pre
transplantation. In the group receiving BuCy, 81 patients (69%)
are alive with a median follow up of 20.2 months (range, 5.3–97.5).
In the HDMgroup, 31 patients (88%) are alive with a median follow
up of 18.7 months (range, 3.8–55.4). The median relapse free sur-
vival (RFS) for patients receiving the BuCy regimen was 3.3 years
and for patients receiving HDM has not yet been observed (p 5
0.052). The median overall survival (OS) for patients receiving the
BuCy regimen was 6.1 years and for patients receiving HDM has
not been observed. Patients treated with BuCy achieved granulocyte
count .500/mL by day 10 (range, 9–13) whereas patients treated
with HDM recovered by day 13 (range, 10–17) post-transplant
(p\0.001). Patients achieved platelet counts greater than 20,000/
mL at a median of 12 days (range, 8–46) after BuCy and by 13 days
(range, 8–27) after HDM treatment (p 5 0.039). Treatment related
mortality (TRM) was documented in 7 patients (5.9%) in the BuCy
group and 2 patients (5.7%) in the HDM group. Bacteremia was
documented in 19 patients (16%) in the BuCy group and 10 patients
(28%) in the HDM group. BuCy led to faster hematopoietic recov-
ery compared to HDM. RFS, OS and TRM were similar. BuCy and
HDMconfer similar long-term outcomes with comparable toxicities
as conditioning regimens prior to ASCT in patients withMM. Stud-
ies of tandem transplantation might benefit from using busulfan
based regimen in place of a second melphalan-based regimen.187
MAINTENANCE THERAPY WITH LOW DOSE THALIDOMIDE, DEXAMETH-
ASONE, AND CLARITHROMYCIN (BIAXIN) (BLT-D) FOLLOWING AUTOL-
OGOUS TRANSPLANT (ASCT) FOR MULTIPLE MYELOMA (MM)
Holmberg, L.A.1,2, Bensinger, W.I.1,2 1Fred Hutchinson Cancer Research
Center, Seattle, WA; 2University of Washington School of Medicine,
Seattle, WA
Since relapse remains amajor problem after ASCT forMM, inves-
tigators have looked at the role of maintenance therapy post trans-
plant. It is not yet established as to what maintenance regimen is
best nor what is the optimal duration for therapy. M. Coleman et al
(Leukemia and Lymphoma 43: 1777, 2002) pioneered a regimen of
BLT-D to treat non-transplant MM patients, with high CR/PR
rate(93%). Thus, it seemed reasonable to study the regimen of
BLT-D as maintenance therapy after ASCT for MM. Twenty-seven
patients (stage II, n 5 8; stage III, n 5 19 by Durie-Salmon) were
treated. Before ASCT, 52% of patients received Thalidomide; 37%
received . one regimen (range 2–4) prior to chemomobilization of
PBSC. At time of ASCT, 20% of patients were in CR/nCR. All pa-
tients were conditioned with melphalan 200 mg/m2. At 30–120
days after recovery fromacute toxicity ofASCT,patientswere treated
withBiaxin 250mgpobid, dexamethasone 20mgpoweekly andTha-
lidomide beginning dose 50mg po daily forD1–14, then increased to
100mgpodaily. Aspirinwas used forDVTprevention. After one year
of combination therapy, dexamethasone and Biaxin were stopped.
Thalidomidewas continued as long as tolerated until diseaseprogres-
sion. One patient withdrew from therapy to undergo elective 2nd
ASCT.Neuropathywas themost common toxicity; 11 patients(41%)
stopped because of unimproved $ grade 2 neuropathy, median 12
months of therapy (range 6–30), and 7 patients(30%) required dose
reduction of Thalidomide. One patient stopped Thalidomide for
rash. Nine patients(33%) had dose reduction of dexamethasone.
Median time of Thalidomide therapy for all patients is 15 months
(range 3–43). The number of infections included: pneumonia (n 5
3), viral upper respiratory (n 5 2), sinusitis (n 5 1), and bronchitis
(n 5 3). As of 9/08, 22 patients(82%) remain alive, with median
follow-up of 3.54 years (range 1.98–4.19). Five patients have died
due to infection (n 5 1), MM (n 5 3), and complications of 2nd
ASCT (n5 1). Fifteen patients(56%) of 27 remain alive without dis-
ease progression,medianTTPwas 18months (range 3–39). Four pa-
tients remain on therapy at 25–43 months. In summary, BLT-D can
